Antigen-specific immunotherapy for human papillomavirus 16 E7-expressing tumors grown in the liver

Journal of Hepatology

Volumn 33, Issue 1, 2000, Pages 91-98

  Chen, Chien Hung ^b   Suh, Kwang Wook ^c   Ji, Hongxiu ^c   Choti, Michael A ^c   Pardoll, Drew M ^c   Wu, T C ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NONE

Author keywords

Antigen specific; Hepatic tumor; Human papillomavirus; Immunotherapy; Liver; Lysosome associated membrane protein 1; Vaccine; Vaccinia

Indexed keywords

CANCER VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; LIVER TUMOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINIA; VIRUS EXPRESSION; WART VIRUS;

EID: 0343457893     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(00)80164-6     Document Type: Article

References (49)

1. Pardoll DM. Cancer vaccines. Nat Med. 4:1998;525-531.
2. Greten TF, Jaffee EM. Cancer vaccines. J Clin Oncol. 17:1999;1047-1060.
3. Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity. 10:1999;281-287.
4. Van den Eynde BJ, van der Bruggen P. T cell defined tumor antigens. Curr Opin Immunol. 9:1997;684-693.
5. Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today. 18:1997;175-182.
6. + T cell responses in anti-tumor immunity. Curr Opin Immunol. 10:1998;588-594.
7. Wu TC, Guarnieri FG, Staveley OCKF, Viscidi RP, Levitsky HI, Hedrick L, et al. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci U S A. 92:1995;11671-11675.
8. Chen JW, Murphy TL, Willingham MC, Pastan I, August JT. Identification of two lysosomal membrane glycoproteins. J Cell Biol. 101:1985;85-95.
9. Guarnieri FG, Arterburn LM, Penno MB, Cha Y, August JT. The motif Tyr-X-X-hydrophobic residue mediates lysosomal membrane targeting of lysosome-associated membrane protein 1. J Biol Chem. 268:1993;1941-1946.
10. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56:1996;21-26.
11. Ji H, Chang EY, Lin KY, Kurman RJ, Pardoll DM, Wu TC. Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein. Int J Cancer. 78:1998;41-45.
12. Gilboa E. Murine models for cancer immunotherapy using cytokine gene modified tumor vaccines. Forni G, Foa R, Santoni A, Frati L. Cytokine-Induced Tumor Immunogenicity. 1994;130-143 Academic Press, London.
13. Fidler IJ, Wilmanns C, Staroselsky A, Radinsky R, Dong Z, Fan D. Modulation of tumor cell response to chemotherapy by the organ environment. Cancer Metastasis Rev. 13:1994;209-222.
14. Fukumura D, Yuan F, Monsky WL, Chen Y, Jain RK. Effect of host microenvironment on the microcirculation of human colon adenocarcinoma. Am J Pathol. 151:1997;679-688.
15. Nannmark U, Johansson BR, Bryant JL, Unger ML, Hokland ME, Goldfarb RH, et al. Microvessel origin and distribution in pulmonary metastases of B16 melanoma: implication for adoptive immunotherapy. Cancer Res. 55:1995;4627-4632.
16. + T cells using an ELISPOT assay. J Immunol Methods. 181:1995;45-54.
17. Murali-Krishna K, Altman JD, Suresh M, Sourdive DJ, Zajac AJ, Miller JD, et al. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity. 8:1998;177-187.
18. Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de JB, Drijfhout JW, ter SJ, Melief CJ, Kast WM. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol. 23:1993;2242-2249.
19. McCutcheon M, Wehner N, Wensky A, Kushner M, Doan S, Hsiao L, et al. A sensitive ELISPOT assay to detect low-frequency human T lymphocytes. J Immunol Methods. 210:1997;149-166.
20. Okuda K. Hepatocellular carcinoma: recent progress. Hepatology. 15:1992;948-963.
21. Lygidakis NJ, Pearl A. Metastatic liver disease-a review. Hepatogastroenterology. 44:1997;1484-1487.
22. Ruiz J, Qian C, Prieto J. Gene therapy of liver tumors: principles and applications. Digestion. 59:(Suppl 2):1998;92-96.
23. Schuster MJ, Wu GY. Gene therapy for hepatocellular carcinoma: progress but many stones yet unturned! Gastroenterology. 112:1997;656-659.
24. Chen CH, Wu TC. Experimental vaccine strategies for cancer immunotherapy. J Biomed Sci. 5:1998;231-252.
25. Caruso M, Pham-Nguyen K, Kwong YL, Xu B, Kosai KI, Finegold M, et al. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc Natl Acad Sci USA. 93:1996;11302-11306.
26. Shiratori Y, Kanai F, Hikiba Y, Moriyama H, Hamada H, Matsumura M, et al. Gene therapy for hepatic micrometastasis of murine colon carcinoma. J Hepatol. 28:1998;886-895.
27. Siders WM, Wright PW, Hixon JA, Alvord WG, Back TC, Wiltrout RH, et al. T cell- and NK cell-independent inhibition of hepatic metastases by systemic administration of an IL-12-expressing recombinant adenovirus. J Immunol. 160:1998;5465-5474.
28. Cao G, Kuriyama S, Du P, Sakamoto T, Kong X, Masui K, et al. Complete regression of established murine hepatocellular carcinoma by in vivo tumor necrosis factor alpha gene transfer. Gastroenterology. 112:1997;501-510.
29. Atarashi Y, Yasumura S, Nambu S, Yoshio Y, Murakami J, Takahara T, et al. A novel human tumor necrosis factor alfa mutein, F4614, inhibits in vitro and in vivo growth of murine and human hepatoma: implication for immunotherapy of human hepatocellular carcinoma. Hepatology. 28:1998;57-67.
30. Karpoff HM, D'Angelica M, Blair S, Brownlee MD, Federoff H, Fong Y. Prevention of hepatic tumor metastases in rats with herpes viral vaccines and gamma-interferon. J Clin Invest. 99:1997;799-804.
31. Yoshida H, Enomoto H, Tagawa M, Takenaga K, Tasaki K, Nakagawara A, et al. Impaired tumorigenicity and decreased liver metastasis of murine neuroblastoma cells engineered to secrete interleukin-2 or granulocyte macrophage colony-stimulating factor. Cancer Gene Ther. 5:1998;67-73.
32. Peron JM, Esche C, Subbotin VM, Maliszewski C, Lotze MT, Shurin MR. FLT3-ligand administration inhibits liver metastases: role of NK cells. J Immunol. 161:1998;6164-6170.
33. DeMatos P, Abdel-Wahab Z, Vervaert C, Seigler HF. Vaccination with dendritic cells inhibits the growth of hepatic metastases in B6 mice. Cell Immunol. 185:1998;65-74.
34. Sznol M, Holmlund J. Antigen-specific agents in development. [review] Semin Oncol. 24:1997;173-186.
35. Becker JC, Pancook JD, Gillies SD, Furukawa K, Reisfeld RA. T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J Exp Med. 183:1996;2361-2366.
36. Xiang R, Lode HN, Dolman CS, Dreier T, Varki NM, Qian X, et al. Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy. Cancer Res. 57:1997;4948-4955.
37. Lode HN, Xiang R, Dreier T, Varki NM, Gillies SD, Reisfeld RA. Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood. 91:1998;1706-1715.
38. Guo YJ, Che XY, Shen F, Xie TP, Ma J, Wang XN, et al. Effective tumor vaccines generated by in vitro modification of tumor cells with cytokines and bispecific monoclonal antibodies. Nat Med. 3:1997;451-455.
39. Ganss R, Hanahan D. Tumor microenvironment can restrict the effectiveness of activated anti-tumor lymphocytes. Cancer Res. 58:1998;4673-4681.
40. Shiraki K, Tsuji N, Shioda T, Isselbacher KJ, Takahashi H. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci U S A. 94:1997;6420-6425.
41. + T cell-based immunotherapy interferes with liver tumor progression in a transgenic mouse model. J Immunol. 161:1998;5133-5137.
42. Yee C, Riddell SR, Greenberg PD. Prospects for adoptive T cell therapy. Curr Opin Immunol. 9:1997;702-708.
43. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA. 93:1996;11341-11348.
44. Borysiewicz LK, Fiander A, Nimako M, Man S, Wilkinson GW, Westmoreland D, et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet. 347:1996;1523-1527.
45. McAneny D, Ryan CA, Beazley RM, Kaufman HL. Results of a phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer. Ann Surg Oncol. 3:1996;495-500.
46. Ockenhouse CF, Sun PF, Lanar DE, Wellde BT, Hall BT, Kester K, et al. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J Infect Dis. 177:1998;1664-1673.
47. Hanke T, Blanchard TJ, Schneider J, Hannan CM, Becker M, Gilbert SC, et al. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine. 16:1998;439-445.
48. Hodge JW, McLaughlin JP, Kantor JA, Schlom J. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and anti-tumor responses. Vaccine. 15:1997;759-768.
49. Belyakov IM, Moss B, Strober W, Berzofsky JA. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proc Natl Acad Sci USA. 96:1999;4512-4517.